H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer. Baratchian M, Tiwari R, Khalighi S, Chakravarthy A, et al. Proc Natl Acad Sci U S A 2022;119:e2114324119.

Read + Share

Amedeo Smart

Independent Medical Education

Baratchian M, Tiwari R, Khalighi S, Chakravarthy A, et al. H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer. Proc Natl Acad Sci U S A 2022;119:e2114324119.
PMID: 35584120